DIAGNOS Continues Expansion in Canada with Kick-off of Services in Endocrinology Clinics with Distribution Partner Labtician Ophthalmics
July 27 2022 - 9:00AM
DIAGNOS Inc. (“
DIAGNOS”, the
“
Corporation” or ”we”) (TSX Venture: ADK) (OTCQB:
DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is proud to continue its expansion in Canada
with the kick-off of its services in endocrinology clinics with
distribution partner Labtician Ophthalmics.
DIAGNOS is announcing the kick-off by Labtician
Ophthalmics (“Labtician”) of DIAGNOS’ Pathology Detection Systems
deployment into a network of endocrinology clinics providing care
to over 77,000 patients across Canada. This breakthrough in the
endocrinology clinics market is the result of the partnership
agreement signed by both companies in February 2021 to increase
DIAGNOS’ footprint and accelerate its growth in Canada while aiming
to address growing needs in the monitoring of diabetic and
hypertensive patients with the help of DIAGNOS’ technology.
"Our expansion into the endocrinology market
demonstrates our ability to deliver on our strategy for sustained
growth. Every endocrinology clinic onboarding with our Pathology
Detection Systems lays the groundwork and opportunity to positively
change people's life, while nurturing our growth with the addition
of an important source of recurring revenues", says Mr.
André Larente, President of DIAGNOS. "We are excited to
provide our Artificial Intelligence approach to Diabetes management
through Pathology Detection Systems that empower endocrinologists
to deliver the best possible and most sustainable outcome for
patients".
Diabetes is the primary cause of blindness in
adults aged 20 to 74 years old. Diabetic eye disease is a group of
complications associated with diabetes. These complications include
diabetic retinopathy, diabetic macular edema, cataracts, and
glaucoma. All of them can cause serious vision loss or even
blindness, but fortunately, tools such as those developed by
DIAGNOS exist and allow early detection, timely treatment, and the
prevention of a serious reduction in the quality of life of people
suffering from Diabetes.
“Our decision of teaming-up with DIAGNOS stems
from our desire to satisfy our customers’ demand for detection
systems of ocular pathologies. The sophisticated and ever-evolving
solutions developed by DIAGNOS provide endocrinology clinics with
lightning-fast exam results and harmonized scoring, resulting in
increased quality of care while reducing costs and improving
medical outcomes”, explained Labtician President, Polydor
Strouthos.
About LabticianWith 60 years of history in
Canada, Labtician has evolved from a manufacturer of quality
ophthalmic products for the global market to a specialized
commercialization partner for the Canadian ophthalmic market. In
their capacity as a commercialization partner, they offer the
“complete Canadian solution”. Labtician is actively involved in the
entire commercialization process from pre-launch, to launch and
post-launch. This involves regulatory, market access, importation,
and distribution as well as sales and marketing activities.
Internationally, they offer commercialization expertise through
global partners.
Additional information is available at
www.labtician.com
For further information, please contact:
info@labtician.com
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available at
www.DIAGNOS.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450 678-8882, ext. 224
Email: alarente@DIAGNOS.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024